Risk factors for diabetes insipidus in langerhans cell histiocytosis

@article{Grois2006RiskFF,
  title={Risk factors for diabetes insipidus in langerhans cell histiocytosis},
  author={Nicole Grois and Ulrike P{\"o}tschger and Helmut Prosch and Milen Minkov and Maurizio Aric{\`o} and Jorge Luis Braier and Jan-Inge Henter and Gritta E. Janka-Schaub and Stephan Ladisch and Joerg Ritter and Manuel Steiner and E Unger and Helmut Gadner},
  journal={Pediatric Blood \& Cancer},
  year={2006},
  volume={46}
}
Diabetes insipidus (DI) is the most frequent central nervous system (CNS)‐related permanent consequence in Langerhans cell histiocytosis (LCH), which mostly requires life‐long hormone replacement therapy. In an attempt to define the population at risk for DI, 1,741 patients with LCH registered on the trials DALHX 83 and DALHX 90, LCH I and LCH II were studied. 
Central diabetes insipidus in pediatric patients with Langerhans cell histiocytosis: Results from the JLSG‐96/02 studies
We analyzed central diabetes insipidus (CDI) development in pediatric patients with Langerhans cell histiocytosis (LCH) treated according to the Japan LCH Study Group (JLSG) regimen, which is theExpand
Diabetes insipidus in Langerhans cell histiocytosis: When is treatment indicated?
TLDR
Patients with LCH and DI have a high risk of progression to anterior pituitary dysfunction, with a 54% 10-year risk of growth hormone insufficiency (GHI) and a lesser, but significant risk of deficiency of the other anterior pituitsary hormones. Expand
A Rare Cause of Diabetes Insipidus in Children: Langerhansian Histiocytosis
TLDR
The observation of a 2year-old child who presents with stagnation in weight with polyuria polydipsia of diabetes insipidus, the cause of which is Langerhansian histiocytosis is reported. Expand
Neuroendocrine manifestations of Langerhans cell histiocytosis.
TLDR
Complete hormonal evaluation of pituitary hormones and long-term follow-up of LCH patients are strongly recommended, especially when pituitARY involvement is established. Expand
Endocrine manifestations in Langerhans cell histiocytosis
TLDR
Investigation of endocrine tissues other than the pituitary has also been described but is relatively rare, and further studies are needed to evaluate the effect that endocrine deficiencies exert on the overall prognosis of patients with Langerhans cell histiocytosis. Expand
Langerhans' cell histiocytosis of the temporal bone in an adult with central diabetes insipidus
We present a case of Langerhans’ cell histiocytosis in a 40-year-old woman presenting with central diabetes insipidus and right ear pain. As this disease process is often clinically challenging, theExpand
Multisystem Langerhans Cell Histiocytosis in an infant
TLDR
An interesting case of a 5 month old female diagnosed with multisystem LCH, whose disease process included osseous, pulmonary, gastrointestinal, cutaneous, hematopoietic and neurologic involvement is reported. Expand
Histiocytosis X revealed by diabetes insipidus and skin lesions.
TLDR
An adult case where Langerhans cell histiocytosis presented with diabetes insipidus and cutaneous ulcers is reported. Expand
Individualized treatment approaches for Langerhans cell histiocytosis
TLDR
Clinical presentation of patients with LCH may vary in site and extent of involvement, and in 45% of patients LCH manifests as a multisystem disease. Expand
Epidemiology and Clinical Manifestations of Langerhans Cell Histiocytosis in Children
This chapter recounts the history of classification of LCH, the association with certain risk factors and with other malignancies, and the patterns of disease reported. In it, the history of LCH as aExpand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 33 REFERENCES
Diabetes insipidus and Langerhans cell histiocytosis: a case report of reversibility with 2-chlorodeoxyadenosine.
TLDR
The authors report the successful reversal of DI in a 3-year-old child with established LCH using 2-CDA, an active drug in children and adults with relapsed or refractory LCH. Expand
Diabetes insipidus in Langerhans cell histiocytosis: results from the DAL-HX 83 study.
TLDR
The rapid institution of systemic chemotherapy for disseminated disease seems to prevent the occurrence of DI and may be responsible for the low frequency of DI in the DAL-HX83 study. Expand
Growth and endocrine disorders in multisystem Langerhans' cell histiocytosis
Langerhans' cell histiocytosis is a rare disorder, with diabetes insipidus occurring in up to half of patients. Causes of growth failure include the illness itself, treatments used and growth hormoneExpand
Permanent consequences in Langerhans cell histiocytosis patients: A pilot study from the Histiocyte Society—Late Effects Study Group
TLDR
A retrospective survey was organized to describe the prevalence of PC among long‐term survivors of LCH, and to design a definitive late effects study. Expand
Course and clinical impact of magnetic resonance imaging findings in diabetes insipidus associated with Langerhans cell histiocytosis
TLDR
Diabetes insipidus is the most frequent sequela in Langerhans cell histiocytosis (LCH), and brain magnetic resonance imaging findings in LCH patients with LCH during the disease course are unclear. Expand
Diabetes insipidus secondary to Langerhans' cell histiocytosis: is radiation therapy indicated?
TLDR
It is felt that the standard treatment of RT to all patients with LCH-induced DI is no longer justified and an improved rationale would be rapid initiation of hypothalamic-pituitary irradiation in patients with new symptoms of DI and an abnormal water deprivation test. Expand
Diabetes insipidus associated with Langerhans cell histiocytosis: is it reversible?
TLDR
The most appropriate treatment for reversing diabetes insipidus complicating Langerhans cell histiocytosis is yet to be determined and precise documentation of posterior pituitary dysfunction is essential if the effects of new forms of treatment are to be assessed accurately. Expand
LCH-I: a randomized trial of etoposide vs. vinblastine in disseminated Langerhans cell histiocytosis. The Histiocyte Society.
TLDR
The available evidence leads to the recommendation that the study of etoposide in LCH should be continued, and data on the risk of etOPoside-associated (therapy-induced) malignancy, in the setting of histiocytosis, are reviewed. Expand
Endocrine involvement in pediatric-onset Langerhans' cell histiocytosis: a population-based study.
TLDR
Patients who develop endocrine LCH disorders are at a high risk of neurodegenerative LCH and require long-term follow-up and the chronology of episodes did not support a causal link between pituitary involvement and involvement of other organs. Expand
Treatment strategy for disseminated langerhans cell histiocytosis
TLDR
The shorter duration of active disease, low rate of recurrence and permanent consequences, and improved survival among patients with poor prognosis support the strategy of rapid initiation of a predefined prolonged treatment upon the diagnosis of disseminated LCH. Expand
...
1
2
3
4
...